Precision BioSciences Posts Q2 Loss; PBGENE-HBV Delivers Clinical CccDNA Elimination Data
Precision BioSciences (DTIL) reported a Q2 2026 net loss of $32.7M, an increase from the prior year. The company presented clinical data for PBGENE-HBV, showing cccDNA elimination in hepatitis B patients. PBGENE-DMD, for Duchenne muscular dystrophy, is advancing with initial safety data expected by year-end. Cash reserves total $112.4M, supporting operations through 2028.
How this was made
The 30-second read
Why it matters
The data provides the first in‑human evidence of cccDNA elimination, a key milestone for HBV therapeutics.
Market read
Earnings loss and pioneering trial data create short‑term trading opportunities and long‑term valuation considerations.
What to watch
Potential dilution from future financing and competitive gene‑editing pipelines.
Background
Precision BioSciences reported Q2 loss, cash position, and early Phase 1 data for its hepatitis B gene‑editing program.
Ticker impact
Q2 2026 earnings release and first clinical cccDNA elimination data for PBGENE-HBV.
Potential modest upside on trial data, but downside risk from expanding loss.
Clinical data is primary disclosure for a biotech; earnings loss is new information.
Market effects
Early gene‑editing data may boost biotech sector sentiment.
U.S. biotech investors likely to react; limited global spillover.
Limited to gene‑editing niche, not broad market.
Counterpoint
Losses may outweigh trial optimism, prompting a sell‑off.
Key entities
- companyPrecision BioSciences, Inc.
Clinical‑stage gene‑editing firm (ticker DTIL).
- programPBGENE-HBV
In‑vivo gene‑editing therapy for chronic hepatitis B.